A 16-Week, Open-Label, Multicentre, Randomised, Parallel Study to Evaluate Efficacy and Safety of Repaglinide and Metformin Combination Therapy Compared to Repaglinide Monotherapy in Chinese OAD Naive Type 2 Diabetic Patients.
Phase of Trial: Phase IV
Latest Information Update: 10 Dec 2016
At a glance
- Drugs Metformin; Repaglinide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 24 Sep 2010 Results were presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
- 19 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History